Was the AVITA Medical (RCEL) CEO’s share acquisition an open-market buy?

The CEO’s 5,000-share acquisition was not an open-market buy. It occurred under AVITA Medical’s Employee Share Purchase Plan and is treated as a grant or award exempt under Rule 16b-3(d) and Rule 16b-3(c), typical for compensation-related equity purchases.

What SEC rules govern the AVITA Medical (RCEL) CEO’s ESPP share acquisition?

The acquisition is described as exempt under Rule 16b-3(d) and Rule 16b-3(c). These rules allow certain officer and director equity transactions, such as plan-based grants and purchases, to avoid short-swing profit liability when they follow approved compensation plan terms.

AVITA Medical (RCEL) CEO adds 5,000 shares through ESPP purchase

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

AVITA Medical, Inc. President and CEO Vance Cary Guy acquired 5,000 shares of common stock through the company’s Employee Share Purchase Plan. The shares were purchased at $3.0515 per share, equal to 85% of the closing price on December 1, 2025, for the ESPP period that ran through May 31, 2026.

After this transaction, he holds 40,771 shares directly, a figure that includes unvested restricted stock units. The acquisition is classified as a grant or award and was exempt under Rule 16b-3(d) and Rule 16b-3(c), indicating a compensation-related, routine purchase rather than an open-market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Vance Cary Guy

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,000	$3.0515	$15K

Holdings After Transaction: Common Stock — 40,771 shares (Direct, null)

Footnotes (1)

These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2025 and ended on May 31, 2026 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 1, 2025 (the purchase date of the offering period). Includes unvested RSUs.

Key Figures

Shares acquired: 5,000 shares Purchase price per share: $3.0515 per share Post-transaction holdings: 40,771 shares +3 more

6 metrics

Shares acquired 5,000 shares Common stock acquired under ESPP on May 29, 2026

Purchase price per share $3.0515 per share ESPP purchase price, equal to 85% of closing price on December 1, 2025

Post-transaction holdings 40,771 shares Total common stock held directly after transaction, includes unvested RSUs

ESPP discount 85% Purchase price set at 85% of closing price on December 1, 2025

ESPP purchase period start December 1, 2025 Beginning of ESPP purchase period covering this acquisition

ESPP purchase period end May 31, 2026 End of ESPP purchase period covering this acquisition

Key Terms

Employee Share Purchase Plan, ESPP, Rule 16b-3(d), Rule 16b-3(c), +1 more

5 terms

ESPP financial

"These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP")"

An Employee Stock Purchase Plan (ESPP) is a company program that lets employees buy the company’s shares at a reduced price, usually by setting aside a small portion of their pay over time. It matters to investors because it encourages employees to own part of the business—like giving staff a discounted membership— which can boost commitment and performance, while also potentially increasing the number of shares available and affecting shareholder value.

Rule 16b-3(d) regulatory

"in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)"

Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.

Rule 16b-3(c) regulatory

"in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c)"

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

RSUs financial

"Includes unvested RSUs."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/01/2026 - 04:37 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vance Cary Guy

(Last)

(First)

(Middle)

C/O AVITA MEDICAL 28159 AVENUE STANFORD

SUITE 220

(Street)

VALENCIA

CALIFORNIA

91355

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [ RCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/29/2026		A		5,000⁽¹⁾	A	$3.0515⁽¹⁾	40,771⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares were acquired under the AVITA Medical, Inc. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2025 and ended on May 31, 2026 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 1, 2025 (the purchase date of the offering period).

2. Includes unvested RSUs.

	/s/ Nicole Kelsey, by power of attorney	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did AVITA Medical (RCEL) report for its CEO?

AVITA Medical reported that President and CEO Vance Cary Guy acquired 5,000 shares of common stock. The shares were obtained through the company’s Employee Share Purchase Plan as a compensation-related acquisition, not an open-market purchase, and are classified as a grant or award under SEC rules.

At what price were the new AVITA Medical (RCEL) shares acquired by the CEO?

The 5,000 shares were acquired at $3.0515 per share. This price equals 85% of the closing price of AVITA Medical’s common stock on December 1, 2025, consistent with the terms of the Employee Share Purchase Plan purchase period.

How many AVITA Medical (RCEL) shares does the CEO hold after this transaction?

Following the ESPP acquisition, President and CEO Vance Cary Guy holds 40,771 shares of AVITA Medical common stock directly. This total includes unvested restricted stock units, reflecting both vested and certain unvested equity awards reported in the filing.

What period did the AVITA Medical (RCEL) ESPP purchase cover for this CEO acquisition?

The Employee Share Purchase Plan acquisition relates to a purchase period that began on December 1, 2025 and ended on May 31, 2026. Shares were purchased in accordance with ESPP terms, using a price based on the December 1, 2025 closing price.